The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).
 
Athanassios Argiris
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Genentech/Roche
 
Ju-Whei Lee
No Relationships to Disclose
 
James Stevenson
Research Funding - Merck Sharp & Dohme (Inst); Verastem (Inst)
 
Matthew Gerard Sulecki
No Relationships to Disclose
 
Vladimir Hugec
No Relationships to Disclose
 
Nicholas W. Choong
Employment - Genentech
 
Joel N. Saltzman
Stock and Other Ownership Interests - Foundation Medicine; novartis; Roche
 
Wei Song
No Relationships to Disclose
 
Richard M. Hansen
No Relationships to Disclose
 
Tracey L. Evans
Honoraria - Celgene; Genentech; Genentech (I); Lilly
Consulting or Advisory Role - Celgene; Genentech; Genentech (I); Lilly
Speakers' Bureau - Genentech (I)
Research Funding - Sanofi
Travel, Accommodations, Expenses - Celgene; Genentech; Genentech (I); Lilly; Sanofi
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Joan H. Schiller
No Relationships to Disclose